Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174401 · ClinicalTrials.gov registry record · Phase 4
Rocklatan Retinal Perfusion OCT Study
A Phase 4 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07174401: Clinical Trial Phase 4 study, sponsored by Oregon Health and Science University.
NCT07174401 is a Phase 4 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174401, a Phase 4 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
Primary Outcome
The primary outcome measure will be change in the overall peripapillary NFLP CD measured at 6 months and 11-12 month endpoint visits compared to baseline values.
Interventions
- DRUG Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.
- DEVICE Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01 |
| Est. Completion | 2027-10 |
| Phase | Phase 4 |
What is known before NCT07174401 opens enrollment
NCT07174401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. is the first listed.
NCT07174401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07174401 about?
NCT07174401 is a clinical study titled "Rocklatan Retinal Perfusion OCT Study". The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
What is the current status of trial NCT07174401?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-01. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07174401?
The interventions under investigation include: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. (DRUG), Two optical coherence tomography (OCT) devices will be used to assess blood flow changes. (DEVICE).
Who is sponsoring clinical trial NCT07174401?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07174401's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia